J-C. Eymard

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Who dies from prostate cancer?

Anna Patrikidou, Yohann Loriot, J-C. Eymard et al. · Prostate Cancer and Prostatic Diseases · 2014 · 86 citations

Medicine, Oncology, Urology +12

Abstract S1-6: TAMRAD: A GINECO Randomized Phase II Trial of Everolimus in Combination with Tamoxifen Versus Tamoxifen Alone in Patients (pts) with Hormone-Receptor Positive, HER2 Negative Metastatic Breast Cancer (MBC) with Prior Exposure to Aromatase Inhibitors (AI).

T Bachelot, C. Bourgier, Claire Cropet et al. · Cancer Research · 2010 · 61 citations

Medicine, Oncology, Pharmacology +16

Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer

J-C. Eymard, Franck Priou, Alain Zannetti et al. · Annals of Oncology · 2007 · 55 citations · Full text

Medicine, Oncology, Pharmacology +15

1619O High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcSé Pembrolizumab study

Jean‐Yves Blay, Sylvie Chevret, Nicolas Penel et al. · Annals of Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacology +13